Florian Lüders1, Holger Bunzemeier2, Christiane Engelbertz3, Nasser M Malyar3, Matthias Meyborg3, Norbert Roeder2, Klaus Berger4, Holger Reinecke3. 1. Division of Vascular Medicine, Department of Cardiovascular Medicine, and florian.lueders@ukmuenster.de. 2. Diagnosis-Related Group (DRG) Research Group, University Hospital Muenster, Muenster, Germany; and. 3. Division of Vascular Medicine, Department of Cardiovascular Medicine, and. 4. Institute of Epidemiology and Social Medicine, University Muenster, Muenster, Germany.
Abstract
BACKGROUND AND OBJECTIVES: Despite the many studies showing an association between CKD and a high risk of ischemic events and mortality, the association of CKD with peripheral arterial disease (PAD) still has not been well described. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This large cohort study assessed the association of CKD, even in the earlier stages, with morbidity, short- and long-term outcome, and costs among patients with PAD. RESULTS: We identified 41,882 patients with PAD who had an index hospitalization between January 1, 2009, and December 31, 2011. Of these, 8470 (20.2%) also had CKD (CKD stage 2: n=2158 [26%]; stage 3: n=3941 [47%]; stage 4: n=935 [11%]; stage 5: n=1436 [17%]). The ratio of women to men was 1:1.2. Compared with patients without known CKD, those with CKD had higher frequencies of coronary artery disease (1.8-fold higher; P<0.001), chronic heart failure (3.3-fold higher; P<0.001), and Rutherford PAD categories 5 and 6 (1.8-fold higher; P<0.001); underwent significantly fewer revascularizations (0.9-fold fewer; P<0.001); had a nearly two-fold higher amputation rate (P<0.001); had higher frequencies of in-hospital infections (2.1-fold higher; P<0.001), acute renal failure (2.8-fold higher; P<0.001), and sepsis (1.9-fold higher; P<0.001); had a 2.5-fold higher frequency of myocardial infarction (P<0.001); and had a nearly three-fold higher in-hospital mortality rate (P<0.001). In an adjusted multivariable Cox regression model, CKD remained a significant predictor of long-term outcome of patients with PAD during follow-up for up to 4 years (until December 31, 2012; median, 775 days; 25th-75th percentiles, 469-1120 days); the hazard ratio was 2.59 (95% confidence interval, 2.21 to 2.78; P<0.001). The projected mortality rates after 4 years were 27% in patients without known CKD and 46%, 52%, 72%, and 78% in those with CKD stages 2, 3, 4, and 5, respectively. Lengths of hospital stay and reimbursement costs were on average nearly 1.4-fold higher (P<0.001) in patients who also had CKD. CONCLUSIONS: This analysis illustrates the significant and important association of CKD with in-hospital and long-term mortality, morbidity, amputation rates, duration and costs of hospitalization, in-hospital treatment, and complications in patients with PAD.
BACKGROUND AND OBJECTIVES: Despite the many studies showing an association between CKD and a high risk of ischemic events and mortality, the association of CKD with peripheral arterial disease (PAD) still has not been well described. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This large cohort study assessed the association of CKD, even in the earlier stages, with morbidity, short- and long-term outcome, and costs among patients with PAD. RESULTS: We identified 41,882 patients with PAD who had an index hospitalization between January 1, 2009, and December 31, 2011. Of these, 8470 (20.2%) also had CKD (CKD stage 2: n=2158 [26%]; stage 3: n=3941 [47%]; stage 4: n=935 [11%]; stage 5: n=1436 [17%]). The ratio of women to men was 1:1.2. Compared with patients without known CKD, those with CKD had higher frequencies of coronary artery disease (1.8-fold higher; P<0.001), chronic heart failure (3.3-fold higher; P<0.001), and Rutherford PAD categories 5 and 6 (1.8-fold higher; P<0.001); underwent significantly fewer revascularizations (0.9-fold fewer; P<0.001); had a nearly two-fold higher amputation rate (P<0.001); had higher frequencies of in-hospital infections (2.1-fold higher; P<0.001), acute renal failure (2.8-fold higher; P<0.001), and sepsis (1.9-fold higher; P<0.001); had a 2.5-fold higher frequency of myocardial infarction (P<0.001); and had a nearly three-fold higher in-hospital mortality rate (P<0.001). In an adjusted multivariable Cox regression model, CKD remained a significant predictor of long-term outcome of patients with PAD during follow-up for up to 4 years (until December 31, 2012; median, 775 days; 25th-75th percentiles, 469-1120 days); the hazard ratio was 2.59 (95% confidence interval, 2.21 to 2.78; P<0.001). The projected mortality rates after 4 years were 27% in patients without known CKD and 46%, 52%, 72%, and 78% in those with CKD stages 2, 3, 4, and 5, respectively. Lengths of hospital stay and reimbursement costs were on average nearly 1.4-fold higher (P<0.001) in patients who also had CKD. CONCLUSIONS: This analysis illustrates the significant and important association of CKD with in-hospital and long-term mortality, morbidity, amputation rates, duration and costs of hospitalization, in-hospital treatment, and complications in patients with PAD.
Authors: Ann M O'Hare; Anton N Sidawy; Joe Feinglass; Kendra Magee Merine; Jennifer Daley; Shukri Khuri; William G Henderson; Kirsten L Johansen Journal: J Vasc Surg Date: 2004-04 Impact factor: 4.268
Authors: Francoiş Laliberté; Brahim K Bookhart; Francis Vekeman; Mitra Corral; Mei Sheng Duh; Robert A Bailey; Catherine Tak Piech; Patrick Lefebvre Journal: J Manag Care Pharm Date: 2009-05
Authors: Stephen M Sozio; Paige A Armstrong; Josef Coresh; Bernard G Jaar; Nancy E Fink; Laura C Plantinga; Neil R Powe; Rulan S Parekh Journal: Am J Kidney Dis Date: 2009-04-19 Impact factor: 8.860
Authors: A S Levey; R Atkins; J Coresh; E P Cohen; A J Collins; K-U Eckardt; M E Nahas; B L Jaber; M Jadoul; A Levin; N R Powe; J Rossert; D C Wheeler; N Lameire; G Eknoyan Journal: Kidney Int Date: 2007-06-13 Impact factor: 10.612
Authors: L Pasqualini; G Schillaci; M Pirro; G Vaudo; D Siepi; S Innocente; G Ciuffetti; E Mannarino Journal: J Intern Med Date: 2007-10-01 Impact factor: 8.989
Authors: Nivetha Subramanian; Jialin Han; Nicholas J Leeper; Elsie G Ross; Maria E Montez-Rath; Tara I Chang Journal: Am J Nephrol Date: 2021-05-06 Impact factor: 4.605
Authors: Kamel Mohammedi; Mark Woodward; Yoichiro Hirakawa; Sophia Zoungas; Stephen Colagiuri; Pavel Hamet; Stephen Harrap; Neil Poulter; David R Matthews; Michel Marre; John Chalmers Journal: Cardiovasc Diabetol Date: 2016-09-02 Impact factor: 9.951